Login / Signup

Assessment of Ki-67 and mitoses in pituitary neuroendocrine tumours-Consistency counts.

Paul Benjamin LoughreyChristine GreeneKris D McCombeFatima Abdullahi SidiStephen McQuaidStephen CookeSteven J HunterBrian HerronMárta KorbonitsStephanie G CraigJacqueline A James
Published in: Brain pathology (Zurich, Switzerland) (2024)
Pituitary neuroendocrine tumour Ki-67 proliferation index varies according to the number of tumour cells assessed. Consistent Ki-67 scoring approaches and re-evaluation of the recommended Ki-67 3% cut-off are required to clarify controversies in pituitary neuroendocrine tumour Ki-67 proliferation index assessment.
Keyphrases
  • neoadjuvant chemotherapy
  • signaling pathway
  • induced apoptosis
  • growth hormone
  • squamous cell carcinoma
  • lymph node
  • endoplasmic reticulum stress
  • clinical evaluation